Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$8.43 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:59 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

neovasc inc (NVC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - C$12.75
52 Week Low
08/26/14 - C$4.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOVASC INC (NVC)

Related News

No related news articles were found.

neovasc inc (NVC) Related Businessweek News

No Related Businessweek News Found

neovasc inc (NVC) Details

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; the Neovasc Reducer for the treatment of refractory angina; and a line of advanced biological tissue products called Peripatch that are used as components in third-party medical products comprising transcatheter heart valves. The company also provides a range of custom Peripatch products to industry customers for incorporation into their own products, such as transcatheter heart valves and other specialty cardiovascular devices; and consulting and original equipment manufacturing services to other medical device companies. In addition, it offers a line of collagen-based surgical patch products for use in cardiac reconstruction and vascular repair procedures, as well as other surgeries. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

148 Employees
Last Reported Date: 03/30/15
Founded in 2000

neovasc inc (NVC) Top Compensated Officers

Chief Executive Officer and Non-Independent D...
Total Annual Compensation: C$348.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$278.5K
Chief Operating Officer and President of Neov...
Total Annual Compensation: C$221.5K
Vice President of Research and Development
Total Annual Compensation: C$181.5K
Vice President of Clinical Affairs
Total Annual Compensation: C$162.0K
Compensation as of Fiscal Year 2014.

neovasc inc (NVC) Key Developments

Neovasc Inc. Reports Unaudited Condensed Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Neovasc Inc. reported unaudited condensed consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company has posted total revenue of CAD 2,860,646 against CAD 3,836,135 a year ago. Operating loss was CAD 6,434,593 against CAD 427,958 a year ago. Loss and comprehensive loss for the period was CAD 6,157,843 or CAD 0.10 basic and diluted per share against CAD 380,072 or CAD 0.01 basic and diluted per share a year ago. Cash used in operating activities was CAD 4,292,336 against CAD 773,164 a year ago. Purchase of property, plant and equipment was CAD 490,138 against CAD 65,862 a year ago.

Neovasc Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Neovasc Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported operating loss of CAD 19,166,440, loss and comprehensive loss for the period was CAD 19,061,098 or CAD 0.36 loss per share on revenue of CAD 15,863,451 against operating loss of CAD 7,108,969, loss and comprehensive loss for the period was CAD 6,750,250 or CAD 0.14 loss per share on revenue of CAD 11,747,636 for the same period a year ago. Cash flow used in operating activities of CAD 8,925,347 against CAD 4,683,103 for the same period a year ago. Purchase of property, plant and equipment was CAD 1,248,973 against CAD 1,041,188 for the same period a year ago. Revenues increased 35% year-over-year for the year ended December 31, 2014. The net loss for the quarter ended December 31, 2014 was CAD 7,620,570, or CAD 0.14 basic and diluted loss per share, compared with a loss of CAD 2,211,875, or CAD 0.05 basic and diluted loss per share for the same period in 2013.

Neovasc Inc. Launches Reducer in Select European Countries

Neovasc Inc. announced the Neovasc Reducer has been introduced to select centers in Italy and will shortly be available for routine use at additional sites in Germany, the UK and Switzerland. The first two Italian cases were performed by Dr. Antonio Colombo, Director, Cardiac Cath Lab and Interventional Cardiology Unit, EMO GVM Centro Cuore, Columbus and San Raffaele Hospital, Milan, Italy. The Reducer treats refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms. The Reducer alters blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that can be completed in approximately 30 minutes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVC:CN C$8.43 CAD 0.00

NVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $130.72 USD +0.07
St Jude Medical Inc $73.75 USD -0.40
View Industry Companies

Industry Analysis


Industry Average

Valuation NVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.7x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVASC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at